The EGFR pathway is notoriously dysregulated in a significant subset of GBM, often through gene amplification or mutation (van den Bent et al., 2015; Kuan et al., 2001; Nakada et al., 2011), making the FTO-EREG link a potentially critical upstream regulatory event that fine-tunes EGFR signaling strength (Schmidt et al., 2003; Sunaga and Kaira, 2015). Here, EREG is linked to glioblastoma.